Article Figures & Data
Figures
- Figure 1.
A, B, Startle magnitude and PPI after treatment with CNO. CNO significantly reduced the startle response to 110 and 120 dB startle stimuli (A), but had no significant effect on PPI (B). *p < 0.05.
- Figure 2.
Startle magnitude and PPI after treatment with CNO and PCP. A, B, PCP significantly increased the startle magnitude (A) and disrupted the PPI (B). CNO pretreatment had no effect on the disruptive effects of PCP.
- Figure 3.
Startle magnitude and PPI after treatment with CNO and scopolamine. A, B, Scopolamine significantly increased the startle magnitude (A) and disrupted the PPI (B). CNO pretreatment had no effect on the disruptive effects of scopolamine.
- Figure 4.
Effects of CNO on spontaneous locomotion and amphetamine-induced hyperlocomotion. Rats were pretreated with either vehicle or CNO, followed 20 min later by either vehicle or amphetamine. A–F, CNO at 1 mg/kg (A, B), 2 mg/kg (C, D), or 5 mg/kg (E, F) had no effect on spontaneous locomotion. Neither 1 nor 2 mg/kg CNO altered amphetamine-induced hyperlocomotion (B, D), but 5 mg/kg CNO significantly reduced the effects of amphetamine (F). *p < 0.05, **p < 0.01.
- Figure 5.
Effects of CNO on baseline and amphetamine-induced DA signaling. A, B, Examples of 15 s DA overflow curves in vehicle-treated (A) and CNO-treated (B) rats before (solid) and after (dashed) a dose of 1.5 mg/kg, i.p., d-AMPH. C, D, CNO did not alter stimulated DA release (C) or uptake (D) under baseline conditions. E, F, CNO dose-dependently blunted the increased DA release in response to d-AMPH 30 min after systemic treatment (E); however, there were no significant effects on the magnitude of DA uptake inhibition (F). *p < 0.05
- Figure 6.
A–C, Plasma levels of CNO (A), clozapine (B), and N-Des (C) at various time points after the administration of 5 mg/kg CNO.
In this issue
